Crucell and DSM Announce PER.C6 Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production
13 août 2004 02h08 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Aug. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
Crucell Announces Second Quarter 2004 Results
09 juil. 2004 04h41 HE
|
Crucell N.V.
LEIDEN, The Netherlands, July 9, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the second quarter of 2004....
Crucell -- DSM Biologics Alliance Announces Development Milestone Achievement
07 juil. 2004 02h16 HE
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, July 7, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today the...
GlaxoSmithKline Renews PER.C6(R) License Agreement with Crucell
06 juil. 2004 02h14 HE
|
Crucell N.V.
LEIDEN, The Netherlands, July 6, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that GlaxoSmithKline has decided to renew its PER.C6(R)...
Crucell Discovers Human Monoclonal Antibody that Protects Against SARS
25 juin 2004 02h08 HE
|
Crucell N.V.
LEIDEN, The Netherlands, June 25, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today the discovery of an antibody for protection against SARS...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with Chiron for Monoclonal Antibody Production
15 juin 2004 02h12 HE
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 15, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with Merus for Production of Monoclonal Antibody Combinations
10 juin 2004 02h10 HE
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 10, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
Crucell to Present at Needham & Company Third Annual Biotechnology Conference, June 16
09 juin 2004 08h15 HE
|
Crucell N.V.
LEIDEN, Netherlands, June 9, 2004 (PRIMEZONE) -- Crucell N.V. (Nasdaq:CRXL) has announced its Chief Financial Officer, Leonard Kruimer, will present at the Annual Needham & Company Biotechnology...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with PanGenetics for Monoclonal Antibody Production
08 juin 2004 02h19 HE
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 8, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
Market authorization for PER.C6(R)-based West Nile virus veterinary vaccine in Israel
03 juin 2004 08h13 HE
|
Crucell N.V.
LEIDEN, The Netherlands, June 3, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) has announced market authorization for a West Nile virus veterinary vaccine...